



Press Release

March 8, 2012

Rundbuckstrasse 6
CH – 8212 Neuhausen am Rheinfall / Switzerland
www.lifewatch.com

LifeWatch announces comprehensive cardiac monitoring suite in a technology breakthrough using a single device platform

Neuhausen am Rheinfall/Switzerland – In an industry first and exclusive development, LifeWatch AG (SIX Swiss Exchange: LIFE), a leading wireless monitoring and technology company in the U.S., has announced a comprehensive cardiac monitoring suite embodied in a single technology platform. This software defined medical device encompasses the capabilities of Holter, CEM (auto trigger/auto send and patient activation) as well as the Company’s leading and proprietary ACT Ambulatory Cardiac Telemetry product and service. The Company has conducted and concluded a regulatory review to assure compliance with FDA regulations on this cleared medical device with the proper indications for use.

“The Elite service addresses many of the significant needs identified to LifeWatch by our users over a several year period of time. It is an acknowledgement to these customers that we have listened to their concerns and issues and according to them, responded appropriately to their needs,” stated Dr. Yacov Geva, Chairman and CEO of LifeWatch AG, “The Elite service is arguably the most sophisticated outpatient cardiac monitoring service and technology in the market today”.

A programmable feature switches the device from the advanced ACT III ambulatory ECG telemetry system (with 3-channel ECG and optional 24-48 hour Holter reporting), to a sophisticated Auto-Detect/Auto-Send 3-channel ECG cardiac monitoring system. This state-of-the-art technology also enables a streamlined enrollment process, better and easier onsite inventory control for customers and delivers additional customer efficiencies by eliminating the confusing panoply of inconsistent service and technology choices faced by physicians in busy practices.

The Elite service builds on LifeWatch’s already fielded ACT Ex extended service which allows a physician to order a Holter test prior to determining the need for the ACT Telemetry service. The ACT Ex has improved patient compliance as the patient can seamlessly transition from Holter to ambulatory cardiac telemetry if, after 48 hours of monitoring, there has not been a diagnostic find-

ing and the physician wishes to have the patient monitored for an extended period of time without having to come back to the office and switch out devices.

The addition of the auto trigger/auto send capability of a cardiac event monitor to the ACT platform, closes the loop for the physician by adding this capability to his diagnostic arsenal. If the patient leaves the office with the ACT service and it is discovered, for instance, that the patient didn't meet the criteria for the ACT service, instead of contacting the patient and having them return to the practice to get fitted with another device, a software change is made transparently to the patient and the service now becomes an auto trigger/auto send CEM service. The Elite service makes simplicity an attribute of the present market situation and allows the physician to concentrate on practicing medicine without worrying about monitoring.

It is estimated that approximately 70% of present LifeWatch customers will benefit from this additional capability.

For further information please contact:

Sensus Investor and Public Relations, Zürich:

Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients, to consumers of health and wellness products. LifeWatch has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent company of LifeWatch Services Inc., a leading US-based cardiac monitoring service provider, and manufacturer of telecardiology products. LifeWatch is also introducing a new program for Home Sleep Testing of Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. For additional information, please visit www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is available at <http://production.investis.com/lifewatch/alert-service/>

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER

OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.